3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
2
HIV Infections
2
Acquired Immunodeficiency Syndrome
2
Skin Neoplasms
1
Sarcoma, Kaposi
1
Sarcoma
1
Neoplasms
1
Muscle Neoplasms
1
Hepatitis B
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
AIDS-Related Complex
1
Interventions
ziprasidone
1
tretazicar
1
fludarabine phosphate
1
enadenotucirev
1
atezolizumab
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Vaccines
1
Tumor Necrosis Factor-alpha
1
Tranexamic Acid
1
Tobramycin
1
Spironolactone
1
Sevelamer
1
Rocuronium
1
Radiotherapy
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Nafcillin
1
Molindone
1
Methylprednisolone
1
Lurasidone Hydrochloride
1
Labetalol
1
Interferon-beta
1
Haloperidol
1
Genetic Engineering
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenoviridae Infections
×
Tumor Necrosis Factor-alpha
×
Clear all
NCT04695327
2026-03-06
TUNIMO
TILT Biotherapeutics Ltd.
Phase 1
Completed
32 enrolled